Genetic attenuation of Plasmodium by B9 gene disruption
US9764016B2 · kind B2 · utility
4Cited by
12References
14Claims
0Family size
Inventors
Key dates
| Filing date | Jan 24, 2014 |
| Grant date | Sep 19, 2017 |
| Priority date | — |
| Expiry date | Mar 20, 2034 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are mutant Plasmodium-species parasites that are genetically attenuated (GAP). They retain the ability to infect a host and invade host hepatocytes but subsequently their development is completely arrested within the liver stage of Plasmodium development and the parasites do not reach the blood stage of development. Vaccines and pharmaceutical compositions comprising genetically attenuated Plasmodium sporozoites as well as methods of using the same are likewise provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.